Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.
Read Full NewsNew phase 3 FREXCITE trial tests frexalimab CD40L inhibitor in nrSPMS, comparing on-body subcutaneous vs IV dosing
Findings from a phase 1 study indicated that Lucid-21-302 was generally well tolerated and exhibited dose-proportional exposure, warranting additional study in a phase 2 trial for multiple sclerosis.
Oral Semaglutide May Reduce Heart Failure Risk in Patients With T2D
Upadacitinib Switch from Dupilumab Effective in Head and Neck Atopic Dermatitis
1.
Researchers discover cellular 'doorway' exploited by cancer-causing virus
2.
AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence
3.
Dietary Intervention Shows Promise in Blood Cancers
4.
In inflammatory breast cancer, ER beta regulates estrogen signaling.
5.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
1.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
2.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
3.
Unveiling the Secrets of Early Cancer: Emerging Strategies to Decipher Its Biology
4.
Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound
5.
Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Understanding the causes of anemia in adults beyond nutritional deficiencies
5.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge